Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

IL-6-induction of Nox2 and subsequent decrease of parvalbumin and GAD67 expression in PV-positive interneurons is NFκB-dependent. by Laura L. Dugan (264427)

“…(b) Application of IL-6 to neurons in culture induced Nox2 expression (b, top panel) and DHE oxidation (b, bottom panel and c) that was blocked by the NFκB inhibitor SN50. Dissociated primary neuronal cultures were treated with IL-6 (10 ng/ml) for 24 h in the absence or presence of SN50 (5 µM), an inhibitor of NFκB nuclear translocation. …”

AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

Assays of TUNEL revealed a decreased number of apoptotic cell after oroxylin A treatment. by Shu-Fang Lin (4167091)

Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects: